Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1132 participants.

Also called NCT02937454

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,132 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02937454
  • EudraCT 2016-001467-36
Other papers using this trial's data
  • Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis Circulation, 2023-05-30 DOI, PubMed 37051919, PMC10487376 In the PMC Open Access subset under CC BY-NC-ND.
  • Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function Clinical journal of the American Society of Nephrology : CJASN, 2023-09-01 DOI, PubMed 37382961, PMC10564367 In the PMC Open Access subset under CC BY-NC-ND.
  • Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial Lancet (London, England), 2020-12-12 DOI, PubMed 33197395 PubMed links an erratum for this paper. Erratum: PMID 34838177
  • Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial Cardiovascular diabetology, 2023-08-17 DOI, PubMed 37592272, PMC10436432 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Brazil, Croatia, Georgia, Israel, Italy, Lebanon, Netherlands, Poland, Romania, Singapore, Spain, Sweden, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02937454. Randomized; triple masking; primary purpose treatment. Start 2017-04-03 (actual); primary completion 2020-07-21 (actual). Results posted on 2021-06-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency
Acronym
Affirm-AHF
Condition
Iron Deficiency
Condition
Heart Failure
Intervention (Drug)
ferric carboxymaltose
Intervention (Other)
Normal saline 0.9%
Lead sponsor
Vifor (International) Inc. (class: industry)
Collaborator
Worldwide Clinical Trials (class: other)
Collaborator
Cytel Inc. (class: industry)

Record details

Record id
cardio:ct-nct02937454
Content hash
1df1d171ce54d2a21ee499b4f2cc2779caf853400dffbcc7039ed263796ff3c9